ERBB2 and Marchiafava-Bignami disease: Although the high MBD group showed superior prognosis in the subgroup with negative HER2 and in patients who received endocrine therapy, there were no differences in the subgroup with positive HER2 and in patients who did not receive endocrine therapy.